Pyrimidinyl-pyridazinone derivatives for treating a disease which is influenced by inhibition of met kinase

US9403799B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Oliver Schadt · Rodenbach, DE
• Dieter Dorsch · Ober-Ramstadt, DE
• Frank Stieber · Heidelberg, DE
• Andree Blaukat · Heilbad Heiligenstadt, DE

Key dates

• Filing date: Jan 22, 2015
• Grant date: Aug 2, 2016
• Expiry date: Jan 22, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/2826
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds selected from the group according to claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumors.